Breaking News

Financial Report: Covance

January 25, 2013

Late-Stage revenues up 16% in the quarter

Covance
 
4Q Revenues: $562 million (+5%)

4Q Earnings: $33.9 million (+60%)

YTD Revenues: $2.2 billion (+6%)

YTD Earnings: $94.7 million (-28%)

Comments: Late-Stage Development revenues in the quarter grew 16% to $345 million, led by 22% growth in clinical development and 16% growth in central labs, which offset a decline in market access services. For the year Late-Stage Development revenues grew 13% to $1.3 billion. Early Development revenues were down 7% to $217.4 million in the quarter and $869.5 million for the year, due to declines in toxicology, discovery support, and clinical pharmacology, the impact of the sale of environmental services, and the closure of sites in 2012. Restructuring costs were $6.6 million in the quarter and $73.1 million for the year.

blog comments powered by Disqus
  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important

  • Moore’s Law for More Health

    Moore’s Law for More Health

    Patrick Jordan , Encore Health Resources||June 2, 2015
    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity